In our latest publication in the Journal of Medical Economics, the cost-effectiveness of bimekizumab was assessed for the treatment of psoriatic arthritis in Sweden in collaboration with UCB and others.
According to Quantify Research co-author and payer expert Linnea Oldsberg, the present study “provides important new evidence for decision makers in Sweden to optimally allocate healthcare resources through the analysis of biologic and targeted synthetic DMARDs in PsA.”
Check out the full open access study here!
